K
Kasper Rossing
Researcher at Steno Diabetes Center
Publications - 63
Citations - 5793
Kasper Rossing is an academic researcher from Steno Diabetes Center. The author has contributed to research in topics: Diabetic nephropathy & Diabetes mellitus. The author has an hindex of 34, co-authored 52 publications receiving 5490 citations. Previous affiliations of Kasper Rossing include University of Glasgow & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease
David M. Good,Petra Zürbig,Àngel Argilés,Hartwig W. Bauer,Georg M. N. Behrens,Joshua J. Coon,Mohammed Dakna,Stéphane Decramer,Christian Delles,Anna F. Dominiczak,Jochen H. H. Ehrich,Frank Eitner,Danilo Fliser,Moritz Frommberger,Arnold Ganser,Mark Girolami,Igor Golovko,Wilfried Gwinner,Marion Haubitz,Stefan Herget-Rosenthal,Joachim Jankowski,Holger Jahn,George Jerums,Bruce A. Julian,Markus Kellmann,Volker Kliem,Walter Kolch,Andrzej S. Krolewski,Andrzej S. Krolewski,Mario Luppi,Ziad A. Massy,Michael Melter,Christian Neusüss,Jan Novak,Karlheinz Peter,Kasper Rossing,Harald D. Rupprecht,Joost P. Schanstra,Eric Schiffer,Jens-Uwe Stolzenburg,Lise Tarnow,Dan Theodorescu,Visith Thongboonkerd,Raymond Vanholder,Eva M. Weissinger,Harald Mischak,Philippe Schmitt-Kopplin +46 more
TL;DR: The establishment of a reproducible, high resolution method for peptidome analysis of naturally occurring human urinary peptides and proteins, ranging from 800 to 17,000 Da, using samples from 3,600 individuals analyzed by capillary electrophoresis coupled to MS is reported.
Journal ArticleDOI
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.
Peter Hovind,Lise Tarnow,Kasper Rossing,Peter Rossing,Stefanie Eising,Nicolai Larsen,Christian Binder,Hans-Henrik Parving +7 more
TL;DR: Improved glycemic control, lower blood pressure, and reduced prevalence of smoking rates were associated with the improved prognosis in patients followed for >/=20 years.
Journal ArticleDOI
Progression of nephropathy in type 2 diabetic patients.
Kasper Rossing,Per K. Christensen,Per K. Christensen,Peter Hovind,Peter Hovind,Lise Tarnow,Lise Tarnow,Peter Rossing,Peter Rossing,Hans-Henrik Parving,Hans-Henrik Parving +10 more
TL;DR: The authors' long-term prospective study of type 2 diabetic patients with nephropathy has revealed several modifiable risk factors of enhanced progression in kidney disease and increased mortality.
Journal ArticleDOI
Clinical proteomics: A need to define the field and to begin to set adequate standards.
Harald Mischak,Rolf Apweiler,Rosamonde E. Banks,Mark R. Conaway,Joshua J. Coon,Anna F. Dominiczak,Jochen H. H. Ehrich,Danilo Fliser,Mark Girolami,Henning Hermjakob,Denis F. Hochstrasser,Denis F. Hochstrasser,Joachim Jankowski,Bruce A. Julian,Walter Kolch,Ziad A. Massy,Christian Neusuess,Jan Novak,Karlheinz Peter,Kasper Rossing,Joost P. Schanstra,O. John Semmes,Dan Theodorescu,Visith Thongboonkerd,Eva M. Weissinger,Jennifer E. Van Eyk,Tadashi Yamamoto +26 more
TL;DR: It is argued that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples, but should be to address clinically relevant questions and to improve the state-of-the‐art, both in diagnosis and in therapy of diseases.
Journal ArticleDOI
Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study
TL;DR: It is suggested that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy.